20-656 Phase II
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer (View details on clinicaltrial.gov)
Safe Care CommitmentGet the latest news on COVID-19, the vaccine and care at Mass General.Learn more
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer (View details on clinicaltrial.gov)
A Phase II Study of Niraparib with Dostarlimab Therapy as Neoadjuvant Treatment for Patients with BRCA-mutated breast cancer (View details on clinicaltrial.gov)
A 2-stage, Lead-in and Randomized, Phase 2, Openlabel study of Darolutamide versus Enzalutamide as Monotherapy on Testosterone Levels Change in Men with Hormone-Naïve Prostate Cancer (ARAMON) (View details on clinicaltrial.gov)
A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease has Progressed on First-Line Osimertinib Therapy (ORCHARD) (View details on clinicaltrial.gov)
A First-in-Human Phase 1b Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 in Adults with Advanced Solid Malignancies (View details on clinicaltrial.gov)
A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors (View details on clinicaltrial.gov)
A First-in-Human Study of Mutant-selective PI3Ka Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer (View details on clinicaltrial.gov)
A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination with Toripalimab in Subjects with Advanced Solid Malignancies including Lymphoma (View details on clinicaltrial.gov)
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX101 Monotherapy and XTX101 and Pembrolizumab Combination Therapy in Patients with Advanced Solid Tumors (View details on clinicaltrial.gov)
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients with Advanced Solid Tumors (View details on clinicaltrial.gov)